Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in Its Phase I Antisense Oligonucleotide Study (ALG-020572-401)

Aligos Therapeutics, Inc. announced that the first chronic hepatitis B patient has been dosed in the multiple ascending dose portion of Study ALG-020572-401 which is evaluating antisense oligonucleotide ALG-020572.